256 related articles for article (PubMed ID: 14755685)
1. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era.
Platz EA; De Marzo AM; Giovannucci E
J Cell Biochem; 2004 Feb; 91(3):553-71. PubMed ID: 14755685
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing.
Okihara K; Nakanishi H; Nakamura T; Mizutani Y; Kawauchi A; Miki T
Int J Urol; 2005 Jul; 12(7):662-7. PubMed ID: 16045559
[TBL] [Abstract][Full Text] [Related]
3. Variants in the prostate-specific antigen (PSA) gene and prostate cancer risk, survival, and circulating PSA.
Severi G; Hayes VM; Neufing P; Padilla EJ; Tilley WD; Eggleton SA; Morris HA; English DR; Southey MC; Hopper JL; Sutherland RL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1142-7. PubMed ID: 16775173
[TBL] [Abstract][Full Text] [Related]
4. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
Jones JS; Follis HW; Johnson JR
Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
6. PSA testing: an evolving relationship with prostate cancer screening.
Constantinou J; Feneley MR
Prostate Cancer Prostatic Dis; 2006; 9(1):6-13. PubMed ID: 16314892
[TBL] [Abstract][Full Text] [Related]
7. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
8. [Advancements in PSA-based screening for prostate cancer].
Ito K
Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
[TBL] [Abstract][Full Text] [Related]
9. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
11. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
13. PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy.
Bratslavsky G; Fisher HA; Kaufman RP; Voskoboynik D; Nazeer T; Mian BM
Urol Oncol; 2008; 26(2):166-70. PubMed ID: 18312936
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
15. Misclassifying the indications for prostate-specific antigen testing may bias case-control studies of the efficacy of prostate cancer screening.
Hoffman RM; Adams-Cameron ML; Murata GH
J Clin Epidemiol; 2004 Oct; 57(10):1071-5. PubMed ID: 15528058
[TBL] [Abstract][Full Text] [Related]
16. Receiver operating characteristics of the prostate specific antigen test in an unselected population.
McLernon DJ; Donnan PT; Gray M; Weller D; Sullivan F
J Med Screen; 2006; 13(2):102-7. PubMed ID: 16792835
[TBL] [Abstract][Full Text] [Related]
17. [Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group].
Noguchi S; Satomi Y; Sakai N; Takemura H; Ikeda S; Okui N; Kobayashi M; Fukuoka H; Furuhata A
Hinyokika Kiyo; 2008 Mar; 54(3):197-201. PubMed ID: 18411775
[TBL] [Abstract][Full Text] [Related]
18. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
20. Evaluating localized prostate cancer and identifying candidates for focal therapy.
Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
